Pharmacological mechanisms of puerarin in the treatment of Parkinson's disease: An overview

被引:2
|
作者
Zhang, Nianping [1 ,2 ]
Guo, Peng [3 ]
Zhao, Yan [4 ]
Qiu, Xiao [2 ]
Shao, Shuai [5 ]
Liu, Zhenzhong [6 ]
Gao, Zong [7 ]
机构
[1] Shandong Univ Tradit Chinese Med, Postdoctoral Mobile Stn, Jinan 250355, Shandong, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Expt Ctr, Jinan 250355, Shandong, Peoples R China
[3] Jinan Third Peoples Hosp, Dept Neurol, Jinan 250132, Shandong, Peoples R China
[4] Jinan Third Peoples Hosp, Dept Hand & Upper Limb Surg, Jinan 250132, Shandong, Peoples R China
[5] Jingmen Peoples Hosp, Dept Reprod Med, Jingmen 448000, Hubei, Peoples R China
[6] North Sichuan Med Coll, Sch Publ Hlth, Nanchong 637100, Peoples R China
[7] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Neurosurg, 16369 Jingshi Rd, Jinan 250014, Shandong, Peoples R China
关键词
Parkinson 's disease; Puerarin; Pharmacological mechanism; Dopaminergic neurons; Traditional Chinese medicine monomer; PROTECTS DOPAMINERGIC-NEURONS; UBIQUITIN-PROTEASOME SYSTEM; IN-VITRO; ISOFLAVONE PUERARIN; COUPLED RECEPTOR; OXIDATIVE STRESS; PI3K/AKT PATHWAY; O-GLCNACYLATION; MOUSE MODELS; PC12; CELLS;
D O I
10.1016/j.biopha.2024.117101
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Puerarin, a monomer of traditional Chinese medicine, is a key component of Pueraria radix . Both clinical and experimental researches demonstrated that puerarin has therapeutic effects on Parkinson 's disease (PD). Puerarin 's pharmacological mechanisms include: 1) Anti-apoptosis. Puerarin inhibits cell apoptosis through the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt) and c-Jun N-terminal kinase (JNK) signaling pathways. Puerarin also exerts a hormone-like effect against cell apoptosis; 2) Anti-oxidative stress injury. Puerarin inhibits the Nrf2 nuclear exclusion through the GSK-3 beta/Fyn pathway to promote the Nrf2 accumulation in the nucleus, and then promotes the antioxidant synthesis through the Nrf2/ARE signaling pathway to protect against oxidative stress; 3) Neuroprotective effects by intervening in the ubiquitinproteasome system (UPS) and autophagy-lysosomal pathway (ALP). Puerarin significantly enhances the activity of chaperone-mediated autophagy (CMA), which downregulates the expression of alpha-synuclein, reduces its accumulation, and thus improves the function of damaged neurons. Additionally, puerarin increases proteasome activity and decreases ubiquitin-binding proteins, thereby preventing toxic accumulation of intracellular proteins; 4) Alleviating inflammatory response. Puerarin inhibits the conversion of microglia to the M1 phenotype while inducing the transition of microglia to the M2 phenotype. Furthermore, puerarin promotes the secretion of anti-inflammatory factor and inhibits the expression of pro-inflammatory factors; 5) Increasing the levels of dopamine and its metabolites. Puerarin could increase the levels of dopamine, homovanillic acid (HVA) and 3,4dihydroxyphenylacetic acid (DOPAC) in the striatum; 6) Promoting neurotrophic factor expression and neuronal repair. Puerarin increases the expression of glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), thereby exerting a neuroprotective effect. Moreover, the regulation of the gut microbiota by puerarin may be a potential mechanism for the treatment of PD. The current review discusses the molecular mechanisms of puerarin, which may provide insight into the active components of traditional Chinese medicine in the treatment of PD.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment
    Fang, Congcong
    Lv, Longqin
    Mao, Shanping
    Dong, Huimin
    Liu, Baohui
    PARKINSONS DISEASE, 2020, 2020
  • [22] THE NEUROPROTECTIVE MECHANISMS OF ACUPUNCTURE TREATMENT IN PARKINSON'S DISEASE
    Park, Hi-Joon
    Kim, Seung-Tae
    Moon, Woongjoon
    Kim, Seung-Nam
    Chae, Younbyoung
    Lee, Hyejung
    JOURNAL OF PHYSIOLOGICAL SCIENCES, 2009, 59 : 51 - 51
  • [23] Mechanisms of motor complications in treatment of Parkinson's disease
    Kumar, A
    Huang, ZG
    de la Fuente-Fernández, R
    PARKINSON'S DISEASE, 2003, 91 : 193 - 201
  • [24] Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson's Disease
    Schneider, Andrew
    Sari, Adam T.
    Alhaddad, Hasan
    Sari, Youssef
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (03) : 195 - 206
  • [25] An Overview of Parkinson's Disease: Curcumin as a Possible Alternative Treatment
    Patel, Arjun
    Olang, Catherine A.
    Lewis, Gregory
    Mandalaneni, Kesava
    Anand, Nikhilesh
    Gorantla, Vasavi Rakesh
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
  • [26] Levodopa delivery systems for the treatment of Parkinson's disease: An overview
    Goole, J.
    Amighi, K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 380 (1-2) : 1 - 15
  • [27] Pharmacological Treatment of Parkinson Disease A Review
    Connolly, Barbara S.
    Lang, Anthony E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (16): : 1670 - 1683
  • [28] Overview of pharmacological treatment of Kawasaki disease
    Onouchi, Z
    Kawasaki, T
    DRUGS, 1999, 58 (05) : 813 - 822
  • [29] Overview of Pharmacological Treatment of Kawasaki Disease
    Zenshiro Onouchi
    Tomisaku Kawasaki
    Drugs, 1999, 58 : 813 - 822
  • [30] Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions
    Heumann, Rolf
    Moratalla, Rosario
    Trinidad Herrero, Maria
    Chakrabarty, Koushik
    Drucker-Colin, Rene
    Ruben Garcia-Montes, Jose
    Simola, Nicola
    Morelli, Micaela
    JOURNAL OF NEUROCHEMISTRY, 2014, 130 (04) : 472 - 489